Ublituximab + Ibrutinib in Select B-cell Malignancies
A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell Malignancies
Sponsor: TG Therapeutics, Inc.
Listed as NCT02013128, this PHASE1/PHASE2 trial focuses on Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma and remains completed. Sponsored by TG Therapeutics, Inc., it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Nov 2022 [monthly]
Completed PHASE1_PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 8 earlier versions
-
Oct 2019 — Nov 2019 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TG Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .